BIRC5 and cancer: Regarding vaccines based on specific LC TAAs, besides NY-ESO-1 and MAGEA1 analyses, MAGEA4 has been analyzed as a universal immunoprevention cancer vaccine (208), and Survivin has been the target of long synthetic peptide (205).